44. Kongress der Deutschen Gesellschaft für Rheumatologie, 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie
31.08. - 03.09.2016, Frankfurt am Main
Poster Freitag, 02.09.2016
Posterwalk – Spondyloarthritiden V
Meeting Abstract
(SP.25)
[Full Text]
No Increase in Incidence of Inflammatory Bowel Disease Among Secukinumab-treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Schreiber S, Sands BE, Baeten D, Huang JQ, Gandhi K, Karyekar C, Fox T, Gaillez C[Full Text]
Meeting Abstract
(SP.26)
[Full Text]
Comparison of Secukinumab and Adalimumab Monotherapy as First-line Biologic Therapy in Patients with Active Psoriatic Arthritis: Proposed Design of a Randomized, Double-blind, Active Control, Multicenter Study
Mpofu S, McInnes I, Ding K, Noseda E, Pricop L[Full Text]
Meeting Abstract
(SP.27)
[Full Text]
Sustained improvement in skin symptoms, physical functioning, and qualitiy of life with secukinumab versus ustekinumab in patients with moderate-to-severe psoriasis and concomitant psoriatic arthritis: 52 week results from the CLEAR study
Thaci D, Gottlieb AB, Blauvelt A, Bhosekar V, Milutinovic M, Karyekar C[Full Text]
Meeting Abstract
(SP.28)
[Full Text]
Therapie-refraktäre Monarthritis des Manubrium-Corpus sterni Gelenks
Braun M, Hartig I, Matveeva FI[Full Text]
Meeting Abstract
(SP.29)
[Full Text]
Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placcebo-controlled trial, FUTURE 1
Rech J, Kavanaugh A, Hall S, Geusens P, Wang Z, Mpofu S[Full Text]
Meeting Abstract
(SP.30)
[Full Text]
Patterns of early Endothelial Progenitor Cell regeneration in axial seronegative spondylarthritis
Patschan S, Vogt M, Bakhtiari D, Henze E, Müller GA, Patschan D[Full Text]
Meeting Abstract
(SP.31)
[Full Text]
Secukinumab improves physical function and quality of life in patients with active ankylosing spondylitis: 2-year data from measure 1, a phase 3 randomised trial
Baraliakos X, Baeten D, Wei JCC, Geusens P, Talloczy Z, Gong Y, Porter B[Full Text]
Meeting Abstract
(SP.32)
[Full Text]
Secukinumab shows significant efficacy in nail psoriasis: week 32 results from the TRANSFIGURE study
Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M[Full Text]
